Evidence map›Paper›PMID 36781490›Full record

Trial reportJournal of gastroenterology2023

Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.

Motohiko Kato, Naoki Hosoe, Takuji Gotoda, Chika Kusano, Mizuki Kuramochi, Hideo Yoshida, Yoshiaki Kimoto, Yukishige Okamura, Hiroyuki Imaeda, Takafumi Ito and 10 more

Abstract readRandomized Controlled TrialMulticenter StudyEquivalence Trial
PubMed Publisher
In one paragraph

Trial report in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Therapeutic potential ofPharmaceutical biology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 2 countries.

Motohiko KatoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. motohikokato@keio.jp.ORCID 0000-0002-7579-1316
Naoki HosoeCenter for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.
Takuji GotodaDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Chika KusanoDepartment of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
Mizuki KuramochiDepartment of Gastroenterology and Hepatology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Hideo YoshidaDepartment of Gastroenterology and Hepatology, Eiju General Hospital, Tokyo, Japan.
Yoshiaki KimotoDivision of Gastrointestinal Endoscopy, NTT Medical Center Tokyo, Tokyo, Japan.
Yukishige OkamuraDepartment of Gastroenterology and Hepatology, Sano Kosei General Hospital, Tochigi, Japan.
Hiroyuki ImaedaDepartment of Gastroenterology, Saitama Medical University Hospital, Saitama, Japan.
Takafumi ItoDepartment of Gastroenterology, Keiyu Hospital, Yokohama, Japan.
Yasuo MiyamotoDepartment of Gastroenterology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Toshiki HoriiDepartment of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
Hideki MoriDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Yuichi MorohoshiDepartment of Gastroenterology and Hepatology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
Akiko OhnoDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
Ryohei KishinoDepartment of Internal Medicine, Saiseikai Central Hospital, Tokyo, Japan.
Yoko KubosawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Kenichi YoshimuraCenter for Integrated Medical Research, Hiroshima University, Hiroshima, Japan.
Naohisa YahagiDivision of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Tokyo, Japan.
Takanori KanaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPKitasato University · JPEiju General Hospital · JPHiroshima University · JPkeiyu Hospital · JPKitasato Institute Hospital · JPKyorin University · JPNational Hospital Organization · JPNihon University · JPNTT Medical Center · JPSaiseikai Central Hospital · JPSaitama Medical University Hospital · JPSapporo Kosei General Hospital · JPTokyo Medical Center · JPYokohama Municipal Citizen's Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVonoprazan, a potassium-competitive acid blocker (VPZ), significantly reduces postoperative bleeding after gastric ESD; however, there is no consensus on the appropriate treatment duration. We conducted a randomized controlled study to demonstrate that the 3-week administration of VPZ is not inferior to the 8-week administration for ulcer healing.

methodsThis is a prospective, open-label multicenter randomized controlled trial. Patients aged 20-85 years undergoing gastric ESD were included in this study. The key exclusion criteria were patients with bleeding tendencies and those taking NSAIDs, steroids, PPIs, or VPZ medications. Eligible patients were randomly assigned to the VPZ 3w or 8w treatment group. The primary endpoint was the proportion of patients with complete closure of the post-ESD wound at 24 weeks after ESD. The key secondary endpoints included the proportion of patients with complete closure of the post-ESD wound at 8 weeks and the proportion of bleeding or perforation more than 3 weeks after ESD.

resultsFrom May 2018 to October 2020, 234 patients were included. The proportion of patients with complete ulcer closure was significantly lower in the 3w group than in the 8w group (70.8% vs. 90.6%) at 8 weeks post-treatment. The complete closure rates at 24 weeks in the 3w and 8w groups were 99.1% and 99.2%, respectively. The absolute difference in the closure rate at 24 weeks was - 0.059% [95% confidence interval (CI) -3.4% to 3.2], and the lower limit of the 95% CI exceeded -10%, the preset threshold. None of the patients developed delayed bleeding 3 weeks after ESD.

conclusionThis multicenter randomized study demonstrated that 3 weeks of treatment with VPZ is sufficient for ulcer healing. Trial registry number. UMIN000031564.

Indexed as

Endoscopic Mucosal ResectionStomach NeoplasmsStomach UlcerHumansProspective StudiesProton Pump InhibitorsPyrrolesSulfonamidesTreatment OutcomeUlcer1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineProton Pump InhibitorsPyrrolesSulfonamidesESDStomachVonoprazanVPZ

Identifiers

PMID36781490
OpenAlexW4320710386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.